A randomized, double-blind phase 1b study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of the NLRP3 inhibitor selnoflast in patients with moderate to severe active ulcerative colitis.

Barbara KlughammerLuca PialiAlexandra NicaSandra NagelLorna BaileyChristoph JochumStanislav IgnatenkoAngela BläuerSabrina DanilinPratiksha GulatiJoanne HaywardPetar ScepanovicJitao David ZhangSatish BhosaleChui Fung ChongAndreas Christ

Published in: Clinical and translational medicine (2023)

ISRCTN16847938.

Keyphrases

double blind
ulcerative colitis
placebo controlled
clinical trial
open label
early onset
high intensity
randomized controlled trial
study protocol